Bicycle radionuclide conjugates (BRCs) have been developed as a unique radiotheranostic modality for imaging and targeting of proteins overexpressed by tumors, and they possess favorable drug-like properties allowing for effective delivery of radioisotopes. Researchers from Bicycletx Ltd. recently presented a new BRC that targets ephrin type-A receptor 2 (EphA2), named BCY-18469.
Molecular glue degraders are compounds intended to prompt the degradation of E3 ubiquitin ligases by engaging and modifying their surface. Molecular glue-induced protein degradation is considered an emerging strategy in drug discovery.
Researchers from Ashvattha Therapeutics LLC recently reported on ASH-41020, a new dendranib compound acting as a CSF-1R inhibitor with anti-inflammatory and immunomodulatory effects.
Researchers from Sichuan University synthesized new pyrazole amides based on the previously described NADH-ubiquinone oxidoreductase (complex I, CI) inhibitor IACS-010759. Subsequent optimization resulted in the identification of SCAL-255 and SCAL-266 as lead candidates with potent CI inhibitory activity.
A different class of antibiotics could ease the increasing resistance triggered by some gram-negative bacteria. LpxC inhibitors are not new, but all attempts to develop them have failed due to cardiovascular toxicity or ineffectiveness. A modification of the structure of these compounds may have solved the problem. Duke University scientists demonstrated the preclinical safety and efficacy of an LpxC inhibitor candidate against a wide selection of these pathogens.
Researchers from China Pharmaceutical University and affiliated organizations have reported the discovery and preclinical evaluation of a novel bromodomain and extra-terminal (BET) inhibitor, DDO-8926, being developed for the management of neuropathic pain.
Researchers from Peking University (PKU) recently presented the discovery and preclinical evaluation of a novel small-molecule inhibitor of pan-αv integrin, C19-9-21, being developed for the treatment of prostate cancer.
Researchers from Washington University in St. Louis and affiliated organizations have provided details on the discovery and preclinical evaluation of [64Cu]NODAGA-PEG4-SL-022-GGS, a novel small peptide imaging agent for evaluating CD38 expression.
RSS
